Cat. No.: DAB-0011756
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human annexin V protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ANXA5 |
| UniProt No. | P08758 |
| Gene ID | 308 |
| Gene Description | Annexin V, also known as PAP-1 or Lipocortin V, is a ~30 kDa protein that binds to phospholipids in a calcium-dependent manner. All annexins contain a putative PKC binding site, but only annexin V has been identified as an inhibitor of this pathway. It may also signal, by direct interaction with VEGFR2 receptor, in the regulation of vascular endothelial cell proliferation. Annexin V preferentially binds phosphatidylserine, in competition with prothrombin, leading to inhibition of blood coagulation at sites of injury preceding contact between lipid components and coagulation factors that initiate thrombosis. The ability of Annexin V to bind specifically and robustly to phosphatidylserine makes it an attractive reagent in detecting apoptotic cells. Annexin V is inducible by glucocorticoids and can be phosphorylated by tyrosine and serine/threonine kinases. It is thought to block production of mediators of inflammation, such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membranes by phospholipase A2. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
